Celgene Cancer Center Consortium – Request for Applications in Cancer Target and Drug Discovery

The Herbert Irving Comprehensive Cancer Center (HICCC) is seeking proposals from the Columbia University research community for collaborative projects focused on the discovery and validation of novel cancer targets and therapeutics. Successful projects will be funded through the Celgene Cancer Center Consortium, which the HICCC formed with the Abramson Cancer Center at the University of Pennsylvania, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Greatest interest exists for targets or mechanisms that have a strong therapeutic hypothesis, a patient population that is, or can be, biomarker defined and a path to clinical development. Funding levels vary according to the project needs and are expected to support projects over a 2-3 year time frame.

To encourage collaboration across the Consortium, a database of investigators who have expressed interest in participating in this program may be accessed at the link provided below. The investigator profiles provided are intended to serve as a tool for networking with other Consortium investigators to enhance collaboration within the Consortium. A template is available (see below) for you to complete if you are interested in submitting your profile or updating current content. Please note that neither collaboration nor submission of an investigator profile is required for application to this funding opportunity.

Application Due Date: Monday, November 27, 2107 by 5:00pm US Eastern Time

Instructions and Application Material: Download
Investigator Profile database: Download
Investigator Profile (blank template): Download

For questions please contact: Emer Smyth, PhD es3551@cumc.columbia.edu